Core Insights - China National Pharmaceutical Group (国药股份) is a leading pharmaceutical commercial enterprise, currently holding a 20% stake in Yichang Humanwell, which is expected to contribute approximately 500 million yuan in investment income in 2024 [1] - The company dominates the pharmaceutical direct sales market in Beijing and has a current market capitalization of approximately 22 billion yuan, which is below the reasonable valuation of 26.5 billion yuan, indicating potential undervaluation [1] - For 2024, the company is projected to achieve revenue of 50.597 billion yuan and a net profit attributable to shareholders of 2 billion yuan, with stable operating cash flow [1] - The pharmaceutical industry is influenced by centralized procurement policies, but fluctuations for distribution companies are relatively minor [1] Institutional View - As of February 13, 2026, the comprehensive target price for the stock is 36.49 yuan, indicating a potential upside of 26.35% from the latest stock price, with a forecasted net profit growth of 1.04% year-on-year for 2025 [2] Stock Performance - Over the past week (February 7-13, 2026), the stock price of China National Pharmaceutical Group experienced slight fluctuations, closing at 28.99 yuan on February 13, reflecting a decline of 0.82% during this period, with a volatility of 1.71% [3] - The stock performance was slightly better than the pharmaceutical commercial sector, which saw a decline of approximately 0.55% during the same timeframe [3] - The highest trading volume reached 138 million yuan on February 9, with a turnover rate of 0.44% on February 13, indicating stable market trading [3] - Technically, the stock price has been hovering around the 20-day moving average of 29.12 yuan, with support at 28.67 yuan and resistance at 29.53 yuan [3]